Abstract
Background
Knowledge of the real-world treatment patterns for non–small-cell lung cancer (NSCLC)
can identify quality-of-care gaps and guide resource allocation needs. Our objective
was to describe the treatment patterns for advanced NSCLC after first-line chemotherapy
in the era before the approval of immunotherapeutic agents.
Materials and Methods
The present was a retrospective observational study of adult patients with advanced
NSCLC (stage IIIB/IV or metastatic recurrence) who had completed a platinum-containing
regimen, with an appropriate tyrosine kinase inhibitor if positive for epidermal growth
factor receptor mutation or anaplastic lymphoma kinase translocation. Eligible patients
initiated second-line chemotherapy from November 2012 through October 2014, recorded
in an oncology record system for U.S. community clinics.
Results
Of 6867 patients with advanced NSCLC, 4188 (61%) initiated and 2707 (39%) completed
platinum therapy, with a tyrosine kinase inhibitor, if appropriate. Subsequently 1889
of 2707 (70%) received second-line chemotherapy, including 1173 within the study period
(844 [72%] nonsquamous, 275 [23%] squamous, and 54 [5%] not otherwise specified).
The mean ± standard deviation patient age was 66 ± 10 years; 54% were male. Of the
94 different second-line regimens, docetaxel was the most common, prescribed to 14%
of the patients overall and 14% and 16% of the nonsquamous and squamous cohorts, respectively.
The median duration was 64 days (range, 1-455 days) and 48 days (range, 1-210 days)
for the nonsquamous and squamous cohorts, respectively. The median duration by regimen
category was 15 to 85 days (overall range, 1-953 days).
Conclusion
These findings show the diversity, short treatment duration, and lack of efficacy
of second-line chemotherapy regimens for NSCLC in the community oncology setting.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Lung CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
National Cancer Institute. SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer. 2015. Available at: http://seer.cancer.gov/statfacts/html/lungb.html. Accessed: November 30, 2015.
Howlader N, Noone AM, Krapcho M, et al, eds. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Statistics Review, 1975-2012 (updated August 20, 2015). National Cancer Institute, Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Accessed: November 30, 2015.
- Lung cancer.N Engl J Med. 2008; 359: 1367-1380
- The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification.J Thorac Oncol. 2015; 10: 1243-1260
- Immunologic checkpoint blockade in lung cancer.Semin Oncol. 2015; 42: 402-417
- Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.Clin Lung Cancer. 2014; 15: 173-181
National Comprehensive Cancer Network. NCCN guidelines: non-small cell lung cancer version 7.2015. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed: November 30, 2015.
- Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2014; 25: iii27-iii39
- Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update.J Clin Oncol. 2015; 33: 3488-3515
- Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.J Thorac Oncol. 2013; 8: 823-859
- 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.Ann Oncol. 2014; 25: 1475-1484
- Second-line and third-line chemotherapy for lung cancer: use and cost.Am J Manag Care. 2008; 14: 297-306
- Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy.J Thorac Oncol. 2011; 6: 365-371
- Treatment patterns and healthcare costs among patients with advanced non–small-cell lung cancer.Lung Cancer Manage. 2013; 2: 189-197
- Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.Lung Cancer. 2013; 82: 469-476
- Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.Lung Cancer. 2015; 87: 176-185
Flatiron Health. Available at: http://www.flatiron.com/life-sciences. Accessed: November 30, 2015.
Health Insurance Portability and Accountability Act of 1996. Available at: https://www.cms.gov/Regulations-and-Guidance/HIPAA-Administrative-Simplification/HIPAAGenInfo/Downloads/HIPAALaw.pdf. Accessed: November 30, 2015.
- Creating a process to standardize regimen order sets within an electronic health record.J Oncol Pract. 2011; 7: e8-e14
- Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients.Respir Res. 2013; 14: 139
- Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: are patients undertreated?.Cancer. 2015; 121: 2562-2569
- Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology.Tumour Biol. 2015; 36: 9641-9648
- Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.Lung Cancer. 2015; 87: 193-200
- Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.J Cancer Res Clin Oncol. 2014; 140: 1783-1793
- The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population.APMIS. 2015; 123: 108-115
- EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence.Int J Clin Exp Pathol. 2013; 6: 2800-2812
- ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.Clin Cancer Res. 2013; 19: 4273-4281
- Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.Lung Cancer. 2012; 77: 460-463
- Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med. 2010; 363: 1693-1703
Reference
National Center for Health Statistics. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Available at: http://www.cdc.gov/nchs/icd/icd9cm.htm. Accessed: November 27, 2015.
Article info
Publication history
Published online: March 29, 2016
Accepted:
March 22,
2016
Received in revised form:
March 21,
2016
Received:
December 11,
2015
Identification
Copyright
© 2016 Elsevier Inc. All rights reserved.
